Stein Sundstrøm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stein Sundstrøm has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Stein Kaasa
3 shared publicationsUlf Aasebø
3 shared publicationsPaal Brunsvig
2 shared publications- Anne-Birgitte Jacobsen
Department of Oncology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway
1 shared publication - Nina Gunnes
Department of Biostatistics, University of Oslo, P.O. Box 1122 Blindern, N-0317 Oslo, Norway
1 shared publication Norwegian Lung Cancer Study Group
1 shared publication
Latest Publications
- Open Access
- 3 September 2018
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 138 (13)
S.H. Sundstrøm responds
03.09.2018: Medisinsk etikk - Nye kreftlegemidler som har dokumentert effekt og markedstilgang i Norge, men som venter på vurdering i Beslutningsforum, setter onkologer i utfordrende etiske situasjoner.
- 3 September 2018
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 138 (13)
Open AccessS.H. Sundstrøm responds
03.09.2018: Medisinsk etikk - Nye kreftlegemidler som har dokumentert effekt og markedstilgang i Norge, men som venter på vurdering i Beslutningsforum, setter onkologer i utfordrende etiske situasjoner.
- Open Access
- 20 August 2013
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 133 (15) , 1551
Brystbevarende kirurgi – alltid riktig?
- 20 August 2013
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 133 (15) , 1551
Open AccessBrystbevarende kirurgi – alltid riktig?
- Open Access
- 24 April 2013
- Published by Springer Nature in Diagnostic Pathology
- Vol. 8 (1) , 67
Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II
The WHO classification system for astrocytomas is not considered optimal, mainly because of the subjective assessment of the histopathological features. Few prognostic variables have been found that stratify the risk of clinical progression in patients with grade II astrocytoma. For that reason there is a continuous search for biomarkers that can improve the histopathological diagnosis and prognostication of these tumours.
- 24 April 2013
- Published by Springer Nature in Diagnostic Pathology
- Vol. 8 (1) , 67
Open AccessExpression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II
The WHO classification system for astrocytomas is not considered optimal, mainly because of the subjective assessment of the histopathological features. Few prognostic variables have been found that stratify the risk of clinical progression in patients with grade II astrocytoma. For that reason there is a continuous search for biomarkers that can improve the histopathological diagnosis and prognostication of these tumours.
- 7 September 2011
- Published by Springer Nature
- p. 453-459
Palliative External Beam Thoracic Radiation Therapy of Non-Small Cell Lung Cancer
- 7 September 2011
- Published by Springer Nature
- p. 453-459
Palliative External Beam Thoracic Radiation Therapy of Non-Small Cell Lung Cancer
- Open Access
- 30 April 2009
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 9 (1) , 28
Assessing quality of life in a randomized clinical trial: Correcting for missing data
Health-related quality of life is a topic of current interest. This paper considers a randomized phase III study of radiation therapy with concurrent chemotherapy (docetaxel) versus radiation therapy alone in non-small cell lung cancer, stage III A/B. Longitudinal data on quality of life have been obtained through repeated administration of a multi-item questionnaire (EORTC QLQ-C30) developed by the European Organisation for Research and Treatment of Cancer. Missingness in the data is owing to patients having failed to complete the questionnaire at some of the scheduled filling-in times.
- 30 April 2009
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 9 (1) , 28
Open AccessAssessing quality of life in a randomized clinical trial: Correcting for missing data
Health-related quality of life is a topic of current interest. This paper considers a randomized phase III study of radiation therapy with concurrent chemotherapy (docetaxel) versus radiation therapy alone in non-small cell lung cancer, stage III A/B. Longitudinal data on quality of life have been obtained through repeated administration of a multi-item questionnaire (EORTC QLQ-C30) developed by the European Organisation for Research and Treatment of Cancer. Missingness in the data is owing to patients having failed to complete the questionnaire at some of the scheduled filling-in times.
- 1 October 2006
- Vol. 1 (8) , 816-24
Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy?
Patient-assessed health-related quality-of-life (HRQOL) scores, together with demographic and clinical factors in stage III non-small cell lung cancer (NSCLC) patients, are important prognostic factors for survival and may be helpful in determining thoracic radiotherapy (TRT) strategy. In a previously published randomized trial, 301 patients were treated with different palliative radiotherapy schedules, comparing short-term hypofractionated TRT (arm A: 17 Gy/2 fractions [n = 105]) with more protracted TRT (arm B: 42 Gy/15 fractions [n = 104]); arm C: 50 Gy/25 fractions [n = 92]). Baseline HRQOL, demographic, and clinical data were available for all patients. All possible prognostic factors from univariate analysis were entered into the Cox multivariate regression model to identify variables of independent prognostic relevance. Overall survival was similar, whereas long-term survival was restricted to higher-dose radiotherapy with 3-year survival rates of 1, 8, and 6% (p = 0.40) and 5-year survival rates of 0, 4, and 3% (p = 0.12) in arms A, B, and C, respectively. In univariate analysis, Karnofsky performance status, use of analgesics, and weight loss were highly significant non-HRQOL factors (p < 0.001), and physical function, appetite loss, cough, and pain were the most powerful HRQOL factors (p < 0.001). In multivariate analysis, appetite loss appeared as the most powerful independent prognostic indicator. In the group of patients treated with protracted fractionation (n = 196), the 2-, 3-, and 5-year survival rates in patients with no appetite loss (n = 95) were 22% (21/95), 12% (11/95), and 8% (8/95) compared with 3% (3/101), 1% (1/101), and 1% (1/101) in patients with appetite loss present at baseline (n = 101). In addition to performance status and weight loss, patient-reported appetite loss should be assessed in stage III NSCLC patients before administrating TRT; such assessment is a valuable tool for selecting patients to normofractionated or lower-dose hypofractionated palliative TRT.
- 1 October 2006
- Vol. 1 (8) , 816-24
Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy?
Patient-assessed health-related quality-of-life (HRQOL) scores, together with demographic and clinical factors in stage III non-small cell lung cancer (NSCLC) patients, are important prognostic factors for survival and may be helpful in determining thoracic radiotherapy (TRT) strategy. In a previously published randomized trial, 301 patients were treated with different palliative radiotherapy schedules, comparing short-term hypofractionated TRT (arm A: 17 Gy/2 fractions [n = 105]) with more protracted TRT (arm B: 42 Gy/15 fractions [n = 104]); arm C: 50 Gy/25 fractions [n = 92]). Baseline HRQOL, demographic, and clinical data were available for all patients. All possible prognostic factors from univariate analysis were entered into the Cox multivariate regression model to identify variables of independent prognostic relevance. Overall survival was similar, whereas long-term survival was restricted to higher-dose radiotherapy with 3-year survival rates of 1, 8, and 6% (p = 0.40) and 5-year survival rates of 0, 4, and 3% (p = 0.12) in arms A, B, and C, respectively. In univariate analysis, Karnofsky performance status, use of analgesics, and weight loss were highly significant non-HRQOL factors (p < 0.001), and physical function, appetite loss, cough, and pain were the most powerful HRQOL factors (p < 0.001). In multivariate analysis, appetite loss appeared as the most powerful independent prognostic indicator. In the group of patients treated with protracted fractionation (n = 196), the 2-, 3-, and 5-year survival rates in patients with no appetite loss (n = 95) were 22% (21/95), 12% (11/95), and 8% (8/95) compared with 3% (3/101), 1% (1/101), and 1% (1/101) in patients with appetite loss present at baseline (n = 101). In addition to performance status and weight loss, patient-reported appetite loss should be assessed in stage III NSCLC patients before administrating TRT; such assessment is a valuable tool for selecting patients to normofractionated or lower-dose hypofractionated palliative TRT.
- 1 May 2005
- Published by Elsevier in Lung Cancer
- Vol. 48 (2) , 251-261
Second-line chemotherapy in recurrent small cell lung cancer
- 1 May 2005
- Published by Elsevier in Lung Cancer
- Vol. 48 (2) , 251-261
Second-line chemotherapy in recurrent small cell lung cancer
- 1 May 2005
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 75 (2) , 141-148
Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study
- 1 May 2005
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 75 (2) , 141-148
Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study